HK1199710A1 - Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers rdea119/bay869766 - Google Patents

Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers rdea119/bay869766

Info

Publication number: HK1199710A1
Authority: HK; Hong Kong
Prior art keywords: rdea119; bay869766; bay; treatment; pharmaceutical combinations
Prior art date: 2009-03-11

Application number

HK15100195.6A

Other languages

English (en)

Chinese (zh)

Inventor

．查普曼

Original Assignee

Ardea Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-03-11

Filing date

2015-01-08

Publication date

2015-07-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42135921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1199710(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-01-08 Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc

2015-07-17 Publication of HK1199710A1 publication Critical patent/HK1199710A1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pathology (AREA)
Radiology & Medical Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HK15100195.6A 2009-03-11 2015-01-08 Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers rdea119/bay869766 HK1199710A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US15940309P	2009-03-11	2009-03-11

Publications (1)

Publication Number	Publication Date
HK1199710A1 true HK1199710A1 (en)	2015-07-17

Family

ID=42135921

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK12110337.7A HK1169603A1 (en)	2009-03-11	2012-10-18	Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
HK15100195.6A HK1199710A1 (en)	2009-03-11	2015-01-08	Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers rdea119/bay869766

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HK12110337.7A HK1169603A1 (en)	2009-03-11	2012-10-18	Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers

Country Status (23)

Country	Link
US (2)	US8673876B2 (xx)
EP (1)	EP2405908B1 (xx)
JP (2)	JP5767122B2 (xx)
KR (1)	KR20110132371A (xx)
CN (2)	CN102421427B (xx)
AU (1)	AU2010224044A1 (xx)
BR (1)	BRPI1009448A2 (xx)
CA (2)	CA2972379A1 (xx)
CL (1)	CL2011002233A1 (xx)
CO (1)	CO6430423A2 (xx)
CR (1)	CR20110479A (xx)
CU (1)	CU20110170A7 (xx)
DO (1)	DOP2011000282A (xx)
EA (1)	EA201101302A1 (xx)
EC (1)	ECSP11011314A (xx)
HK (2)	HK1169603A1 (xx)
IL (1)	IL214749A0 (xx)
MA (1)	MA33091B1 (xx)
MX (1)	MX2011009498A (xx)
PE (1)	PE20120105A1 (xx)
SG (1)	SG174272A1 (xx)
TN (1)	TN2011000455A1 (xx)
WO (1)	WO2010105110A1 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7723477B2 (en)	2005-10-31	2010-05-25	Oncomed Pharmaceuticals, Inc.	Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CN103002911B (zh)	2008-09-26	2015-08-26	昂考梅德药品有限公司	卷曲蛋白结合药剂及其应用
TWI535445B (zh)	2010-01-12	2016-06-01	安可美德藥物股份有限公司	Ｗｎｔ拮抗劑及治療和篩選方法
WO2013001372A2 (en) *	2011-06-30	2013-01-03	University Of Oslo	Methods and compositions for inhibition of activation of regulatory t cells
EP2788378A4 (en) *	2011-12-09	2015-09-09	Oncomed Pharm Inc	ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
CA2890238A1 (en)	2012-11-02	2014-05-08	Merck Patent Gmbh	Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
US9359444B2 (en)	2013-02-04	2016-06-07	Oncomed Pharmaceuticals Inc.	Methods and monitoring of treatment with a Wnt pathway inhibitor
EP2848246A1 (en) *	2013-09-13	2015-03-18	Bayer Pharma Aktiengesellschaft	Pharmaceutical compositions containing refametinib
ES2648267T3 (es) *	2013-09-13	2017-12-29	Bayer Pharma Aktiengesellschaft	Composiciones farmacéuticas que contienen refametinib
WO2015196072A2 (en)	2014-06-19	2015-12-23	Whitehead Institute For Biomedical Research	Uses of kinase inhibitors for inducing and maintaining pluripotency

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9925958D0 (en)	1999-11-02	1999-12-29	Bundred Nigel J	Therapeutic use
AU2002234165A1 (en) *	2000-11-03	2002-05-27	Tularik, Inc.	Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
WO2003030908A2 (en)	2001-10-09	2003-04-17	The University Of Cincinnati	Inhibitors of the egf receptor for the treatment of thyroid cancer
CA2522845A1 (en) *	2003-04-25	2004-11-11	Gilead Sciences, Inc.	Kinase inhibitor phosphonate conjugates
KR20070107004A (ko) *	2004-12-17	2007-11-06	스미스클라인 비이참 (코르크) 리미티드	암 치료 방법
WO2006076463A2 (en)	2005-01-12	2006-07-20	Amgen Inc.	Kinase-directed, activity-based probes
WO2006090931A1 (ja) *	2005-02-28	2006-08-31	Eisai R & D Management Co., Ltd.	スルホンアミド化合物の抗癌剤との新規併用
US8101799B2 (en) *	2005-07-21	2012-01-24	Ardea Biosciences	Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
WO2009018238A1 (en) *	2007-07-30	2009-02-05	Ardea Biosciences, Inc.	Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
CA2618218C (en) *	2005-07-21	2015-06-30	Ardea Biosciences, Inc.	N-(arylamino)-sulfonamide inhibitors of mek
US8329421B2 (en) *	2007-07-13	2012-12-11	Ventana Medical Systems, Inc.	Methods of predicting response of a neoplasm to an EGFR inhibitor and detecting interactions between EGFR and an EGFR regulatory protein
CN103479604B (zh) *	2007-07-30	2016-08-10	阿迪生物科学公司	作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
US8044240B2 (en) *	2008-03-06	2011-10-25	Ardea Biosciences Inc.	Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
DE102008031039A1 (de)	2008-06-30	2009-12-31	Dömling, Alexander, Priv.-Doz. Dr.	Tarceva zur Anwendung in der Organtransplantation.

2010
- 2010-03-11 AU AU2010224044A patent/AU2010224044A1/en not_active Abandoned
- 2010-03-11 MX MX2011009498A patent/MX2011009498A/es not_active Application Discontinuation
- 2010-03-11 BR BRPI1009448A patent/BRPI1009448A2/pt not_active IP Right Cessation
- 2010-03-11 JP JP2011554220A patent/JP5767122B2/ja not_active Expired - Fee Related
- 2010-03-11 EA EA201101302A patent/EA201101302A1/ru unknown
- 2010-03-11 CA CA2972379A patent/CA2972379A1/en not_active Abandoned
- 2010-03-11 CN CN2010800209977A patent/CN102421427B/zh not_active Expired - Fee Related
- 2010-03-11 US US13/255,278 patent/US8673876B2/en not_active Expired - Fee Related
- 2010-03-11 EP EP10709139.9A patent/EP2405908B1/en active Active
- 2010-03-11 MA MA34134A patent/MA33091B1/fr unknown
- 2010-03-11 PE PE2011001622A patent/PE20120105A1/es not_active Application Discontinuation
- 2010-03-11 SG SG2011064300A patent/SG174272A1/en unknown
- 2010-03-11 CA CA2754913A patent/CA2754913C/en not_active Expired - Fee Related
- 2010-03-11 WO PCT/US2010/027060 patent/WO2010105110A1/en active Application Filing
- 2010-03-11 KR KR1020117021234A patent/KR20110132371A/ko not_active Application Discontinuation
- 2010-03-11 CN CN201310462579.9A patent/CN103948600A/zh active Pending
2011
- 2011-08-18 IL IL214749A patent/IL214749A0/en unknown
- 2011-09-09 TN TN2011000455A patent/TN2011000455A1/fr unknown
- 2011-09-09 CR CR20110479A patent/CR20110479A/es unknown
- 2011-09-09 EC EC2011011314A patent/ECSP11011314A/es unknown
- 2011-09-09 DO DO2011000282A patent/DOP2011000282A/es unknown
- 2011-09-09 CO CO11116967A patent/CO6430423A2/es not_active Application Discontinuation
- 2011-09-09 CU CU20110170A patent/CU20110170A7/es unknown
- 2011-09-09 CL CL2011002233A patent/CL2011002233A1/es unknown
2012
- 2012-10-18 HK HK12110337.7A patent/HK1169603A1/xx not_active IP Right Cessation
2013
- 2013-11-18 US US14/082,681 patent/US9220696B2/en not_active Expired - Fee Related
2014
- 2014-09-04 JP JP2014180216A patent/JP5911929B2/ja not_active Expired - Fee Related
2015
- 2015-01-08 HK HK15100195.6A patent/HK1199710A1/xx unknown

Also Published As

Publication number	Publication date
US20140080783A1 (en)	2014-03-20
CN102421427B (zh)	2013-11-06
JP5767122B2 (ja)	2015-08-19
AU2010224044A1 (en)	2011-09-22
TN2011000455A1 (en)	2013-03-27
US20120071435A1 (en)	2012-03-22
EA201101302A1 (ru)	2012-05-30
BRPI1009448A2 (pt)	2016-03-01
PE20120105A1 (es)	2012-02-22
CA2754913A1 (en)	2010-09-16
JP5911929B2 (ja)	2016-04-27
KR20110132371A (ko)	2011-12-07
US8673876B2 (en)	2014-03-18
CA2972379A1 (en)	2010-09-16
JP2012520321A (ja)	2012-09-06
MA33091B1 (fr)	2012-03-01
DOP2011000282A (es)	2011-10-15
HK1169603A1 (en)	2013-02-01
CU20110170A7 (es)	2012-06-21
SG174272A1 (en)	2011-10-28
US9220696B2 (en)	2015-12-29
CN103948600A (zh)	2014-07-30
WO2010105110A1 (en)	2010-09-16
EP2405908B1 (en)	2016-12-21
IL214749A0 (en)	2011-11-30
EP2405908A1 (en)	2012-01-18
CO6430423A2 (es)	2012-04-30
MX2011009498A (es)	2011-10-14
JP2014237716A (ja)	2014-12-18
CL2011002233A1 (es)	2012-02-03
CA2754913C (en)	2017-08-22
CR20110479A (es)	2011-10-24
CN102421427A (zh)	2012-04-18
ECSP11011314A (es)	2011-10-31

Publication	Publication Date	Title
HK1199710A1 (en)	2015-07-17	Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers rdea119/bay869766
HK1224200A1 (zh)	2017-08-18	用於治療胰腺癌的藥物
IL219073A (en)	2016-05-31	A drug combination for cancer treatment
PL2544682T3 (pl)	2016-08-31	Fitokannabinoidy w leczeniu glejaka
HK1215787A1 (zh)	2016-09-15	用於治療疼痛的藥物組合
EP2480687A4 (en)	2013-03-27	METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF THYROID CANCER
IL218971A0 (en)	2012-07-31	Sulfoxide derivatives for the treatment of tumours
IL213761A0 (en)	2011-07-31	Novel ortho-aminoamides for the treatment of cancer
ZA201200944B (en)	2015-07-29	Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
GB0903158D0 (en)	2009-04-08	Cosmetic or pharmaceutical preparation for the skin
IL214349A0 (en)	2011-09-27	Compositions and methods for the treatment of cancer
IL205137A0 (en)	2010-11-30	5-cyanothienopyridines for the treatment of tumours
IL240560A0 (en)	2015-09-24	Preparations and methods for tumor diagnosis and treatment
GB0906159D0 (en)	2009-05-20	Drug combination for the treatment of proteostatic diseases
EP2437738A4 (en)	2012-11-14	METHOD AND COMPOSITIONS FOR CANCER TREATMENT
GB0715790D0 (en)	2007-09-26	Drug combination for the treatment of sialorrhoea
IL210066A0 (en)	2011-02-28	Novel ortho-aminoanilides for the treatment of cancer
EP2361317A4 (en)	2014-01-01	USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER
IL219298A0 (en)	2012-06-28	Triptans for the treatment of psoriasis
EP2411031A4 (en)	2012-08-01	Methods and compositions for the treatment of cancer
IL200753A (en)	2015-06-30	Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
GB201718726D0 (en)	2017-12-27	Phytocannabinoids in the treatment of cancer
HK1139050A1 (en)	2010-09-10	Medicament for the treatment of pneumonia
ZA201005770B (en)	2012-07-25	The treatment of damaged skin
AU2009905926A0 (en)	2009-12-24	Methods and compositions for the treatment of osteoarticular disease